Future Directions for IMPAACT in Perinatal Transmission
Future Directions for PMTCT

- There have been great advances in PMTCT research over the years with treatment guidelines evolving.

- The Option B+ strategy combined with recent findings from the START study and the 90-90-90 strategy will likely result in broader access and utilization of combination antiretroviral therapy.

- This will likely drive down further new pediatric HIV infections which are now less than 2% in many settings.
Where are the gaps and opportunities?

- Where then is the best place for perinatal prevention efforts?

- Should it be a separate entity or within general HIV services or treatment services. IF combined, how do we effectively make that transition?
Overall Safety and Long-Term Outcome of Drug Exposure

- Recent research has shown that there is increased risk of prematurity with use of HAART.

- Need to address longer term safety / adverse outcomes of specific ART regimens on child growth and development and Maternal Health.

- What is the risk of emergence of resistance with various ART regimens during pregnancy.
Opportunities for PK and safety of new drugs

- As newer ARV drugs come to the market for adult HIV treatment,

The PK and safety of newer ARV drugs in pregnancy and newborns remains a high priority to address.
Opportunities for primary HIV prevention

What prevention opportunities exist for high risk negative women during pregnancy and breastfeeding?

- Adolescents
  - Adolescents are at high risk of HIV infection
  - Adolescents vulnerable to pregnancy with increased risk of HIV infection to infant
  - Adolescent friendly HIV services are still few.

- Other categories of women?
  - There is a need to promote PREP studies among adolescents and other high risk women to reduce HIV transmission to infants.
What are the other perinatal areas of interest?

- Recent data shows devastating effects of the ZIKA virus on newborns.
  - Would this be the way to go?
  - What is the prevalence of Zika virus among pregnant women?
  - What are the interactions of HIV during pregnancy with other co-infections e.g. Zika virus?
PMTCT has made great strides in reducing new pediatric infections.
Increased access to HAART by women and evolving models of care
Studies on Long term safety of drugs in pregnant women and their children still important.
Studies on PK and safety of new drugs are warranted
Primary prevention studies for high risk women is a priority.
New diseases emerging - Zika virus
How do we move forward perinatal prevention efforts?